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BACKGROUND
Mass treatment with azithromycin is a central component of the new World Health 
Organization (WHO) strategy to eradicate yaws. Empirical data on the effective-
ness of the strategy are required as a prerequisite for worldwide implementation 
of the plan.
METHODS
We performed repeated clinical surveys for active yaws, serologic surveys for latent 
yaws, and molecular analyses to determine the cause of skin ulcers and identify 
macrolide-resistant mutations before and 6 and 12 months after mass treatment 
with azithromycin on a Papua New Guinean island on which yaws was endemic. 
Primary-outcome indicators were the prevalence of serologically confirmed active 
infectious yaws in the entire population and the prevalence of latent yaws with 
high-titer seroreactivity in a subgroup of children 1 to 15 years of age.
RESULTS
At baseline, 13,302 of 16,092 residents (82.7%) received one oral dose of azithromy-
cin. The prevalence of active infectious yaws was reduced from 2.4% before mass 
treatment to 0.3% at 12 months (difference, 2.1 percentage points; P<0.001). The 
prevalence of high-titer latent yaws among children was reduced from 18.3% to 
6.5% (difference, 11.8 percentage points; P<0.001) with a near-absence of high-titer 
seroreactivity in children 1 to 5 years of age. Adverse events identified within 1 week 
after administration of the medication occurred in approximately 17% of the par-
ticipants, included nausea, diarrhea, and vomiting, and were mild in severity. No 
evidence of emergence of resistance to macrolides against Treponema pallidum sub-
species pertenue was seen.
CONCLUSIONS
The prevalence of active and latent yaws infection fell rapidly and substantially 12 
months after high-coverage mass treatment with azithromycin, with the reduction 
perhaps aided by subsequent activities to identify and treat new cases of yaws. Our 
results support the WHO strategy for the eradication of yaws. (Funded by Newcrest 
Mining and International SOS; YESA-13 ClinicalTrials.gov number, NCT01955252.)
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Yaws, an infectious disease caused by Treponema pallidum subspecies pertenue, af-fects mainly children in poor rural com-
munities in tropical countries. This bacterium is 
transmitted by direct skin-to-skin, nonsexual 
contact and causes a chronic, relapsing disease 
that is characterized by highly contagious pri-
mary and secondary cutaneous lesions and by 
noncontagious tertiary destructive lesions of the 
bones.1 Cases are reported currently in 12 coun-
tries in Africa, Asia, and the western Pacific re-
gion, and 42 million people are estimated to be 
at risk for yaws.2
A major campaign in the 1950s and 1960s to 
eradicate yaws by means of community-wide 
treatment with long-acting, injectable penicillin 
reduced the number of cases of the disease by 
95% worldwide; however, yaws was not eradi-
cated.3 The discovery that a single dose of oral 
azithromycin is at least as effective as injectable 
penicillin G benzathine4 prompted the World 
Health Organization (WHO) to develop a new 
azithromycin-based treatment policy in 2012 (the 
Morges strategy).5 The recommendation is initial 
mass treatment of the entire population (often 
called total community treatment) with a single 
dose of oral azithromycin, followed by resurveys 
every 6 months in a targeted treatment program 
to detect and treat newly identified persons with 
active yaws and their contacts.
The Morges strategy has several advantages 
over previous campaigns, including oral versus 
parenteral administration of the drug 6 and mass 
treatment regardless of prevalence of yaws in the 
community versus selective treatment of active 
cases, without treatment of latent cases, which 
can develop into infectious yaws lesions.7,8 In 
earlier campaigns, it was neglect of latent infec-
tion that resulted in the rapid return of the 
disease.9 This risk is greatly reduced by the new 
mass treatment recommendation.10,11
Empirical data on the effectiveness of the 
Morges strategy to stop the transmission of yaws 
in a geographically defined area are required as 
a prerequisite for worldwide implementation of 
the plan. Data to determine the burden of yaws 
in a community include the prevalence of active 
infectious yaws (i.e., skin ulcers or papilloma) 
and the prevalence of seroreactivity among pa-
tients without active yaws; these data indicate, 
respectively, the extent to which yaws transmis-
sion is occurring and the extent of the latent or 
hidden infection in the community.12 We used 
clinical surveys, serologic surveys, and etiologic 
studies of skin ulcers to measure the effect of 
mass azithromycin treatment on the community 
burden of yaws.
ME THODS
STUDY SETTING AND PARTICIPANTS
From April 2013 through May 2014, we conduct-
ed a longitudinal study in all the villages of Lihir 
Island, New Ireland Province, Papua New Guinea. 
Lihir Island consists of 28 villages with a range of 
400 to 600 inhabitants each, and the estimated 
population in 2013 was 16,092 according to a 
regularly updated census. All the villages have 
been reported to have a relatively high prevalence 
of active yaws (range, 0.5 to 3.8%),13 and mass 
treatment with azithromycin had never been at-
tempted before our baseline surveys. An increased 
number of active yaws cases is observed during 
the wet season (January through June).
The implementation of the Morges elimina-
tion strategy in the villages started after baseline 
assessment surveys, in accordance with standards 
advocated by the WHO.5 During the initial mass 
treatment program, everyone older than 2 months 
of age in the study villages was offered azithro-
mycin (Medopharm) at a single oral dose of 
30 mg per kilogram of body weight, up to a 
maximum dose of 2 g. Pregnant women and 
people with a known allergy to macrolides were 
offered penicillin G benzathine at a dose of 
50,000 U per kilogram, administered intramus-
cularly. The WHO provided generic azithromy-
cin, which was purchased at full cost from Medo-
pharm.
The initial mass treatment program was fol-
lowed every 6 months by a targeted treatment 
program, in which surveys were performed that 
consisted of clinical examination of the resident 
population, with treatment of all persons with 
active clinical cases and their contacts (household 
members, classmates, and playmates). Between 
those surveys, patients with active yaws who 
presented to a health care facility (passive case 
finding) and their close contacts were treated.
Treatment was provided without cost to the 
study participants. Passive surveillance for ad-
verse events was undertaken throughout the 
study at the Lihir Medical Center and all periph-
eral health posts. Specific training for health 
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care staff was conducted before the interven-
tions began, with a special emphasis on report-
ing any allergic event or any other adverse event 
that was deemed to be possibly related to the 
intervention, with the use of a standard case-
report form for adverse events. We also per-
formed household surveys 1 week after the ini-
tial distribution of the antibiotic agents to 
monitor for potential adverse events in 60 ran-
domly selected households from 28 villages.
All the participants, or their parent or guard-
ian, provided oral informed consent for screening 
and treatment. In addition, we obtained written 
informed consent from persons with suspected 
active yaws before their enrollment in clinical 
surveys and etiologic studies of ulcers and from 
parents or guardians of children recruited for 
serologic surveys; we obtained verbal agreement 
from the children. The study protocol was ap-
proved by the Medical Research Advisory Com-
mittee of the Papua New Guinea National De-
partment of Health (approval number, 12.36). 
Full details of the study conduct are provided in 
the protocol, available with the full text of this 
article at NEJM.org. The sponsors of the study 
had no role in the design of the study, the col-
lection, analysis, or interpretation of the data, or 
the writing of the manuscript. The first author 
had full access to all the study data and had the 
final responsibility for the decision to submit 
the manuscript for publication.
PROCEDURES
Primary-outcome indicators were the prevalence 
of serologically confirmed active infectious yaws 
in the entire population and the prevalence of 
latent yaws with high-titer seroreactivity (rapid 
plasma reagin [RPR], ≥1:16) in a subgroup of 
children 1 to 15 years of age, at baseline and at 
6 and 12 months. Secondary-outcome indicators 
included the proportion of ulcers caused by 
T. pallidum subspecies pertenue, as assessed with 
the use of a polymerase-chain-reaction (PCR) 
assay, and the proportion of yaws samples with 
genetic mutations associated with macrolide re-
sistance at each time point.
Clinical surveys for active infectious yaws le-
sions were undertaken in the entire resident 
population. Active yaws is usually a visible dis-
ease; hence clinical surveys provide useful knowl-
edge. We undertook screening examination of 
all the villagers, using the WHO yaws-pictorial 
guide.14 A clinical diagnosis of active infectious 
lesions was based on chronic (symptomatic for 
>2 weeks) solitary or multiple ulcers or papillo-
mas (Fig. S1 and S2 in the Supplementary Appen-
dix, available at NEJM.org).15 Serologic confir-
mation of treponemal infection with the use of 
a T. pallidum hemagglutination assay (TPHA) and 
RPR testing was performed in persons with ac-
tive lesions. In resurveys at 6 and 12 months, 
persons with new cases of active yaws were 
classified as absentees from initial treatment 
surveys; previously untreated visitors, returning 
laborers, or migrants with clinically active le-
sions; or previously treated local residents. For 
previously treated persons, we performed a me-
ticulous inquiry to find the source of reinfection.
Serologic screening to detect latent yaws was 
conducted in a subgroup of asymptomatic chil-
dren 1 to 15 years of age in six randomly selected 
villages (chosen with the use of computer-gener-
ated random numbers). Because the random 
sample was regenerated at each survey, villages 
might have been chosen repeatedly. The age cri-
teria for inclusion in the serologic surveys were 
intended to reduce the likelihood of reactive sero-
logic findings related to venereal syphilis. Venous 
blood samples were obtained from assenting 
children for TPHA and qualitative and quantita-
tive RPR testing.
All asymptomatic children with a reactive TPHA 
and an RPR titer of at least 1:2 were classified as 
having latent yaws; those with a high RPR titer 
(≥1:16) were classified as having high-titer latent 
yaws. Children with latent yaws with high titers 
would be more likely than those with low titers 
to have a clinical reactivation with active lesions.9 
We classified asymptomatic children according 
to age (1 to 5 years vs. 6 to 15 years). Seroreac-
tivity in young children (1 to 5 years of age) can 
indicate recent infection, because these children 
are new entrants in the potential pool of suscep-
tible persons. The WHO criteria to certify the 
interruption of transmission include no young 
children with RPR seroreactivity and no new 
cases of active yaws for 3 consecutive years.5
All serologic tests for syphilis were per-
formed at the Lihir Medical Center laboratory, 
with external quality-control testing (i.e., 5% of 
positive and negative samples) performed at Sul-
livan Nicolaides Pathology in Queensland, Aus-
tralia. The laboratory scientists were unaware of 
the antibiotic coverage and clinical outcomes.
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PCR surveillance was performed by analysis 
of swabs obtained during clinical surveys from 
each participant with papillomatous or ulcerative 
lesions. The PCR methods have been described 
previously.16 After every survey, we forwarded 
90 randomly selected specimens to the labora-
tory at the University of Washington, Seattle, for 
molecular testing with the use of PCR to detect 
T. pallidum DNA,17-19 a molecular signature spe-
cific to subspecies pertenue (confirming yaws 
infection),19 evidence of mutations conferring 
resistance to azithromycin,20 and Haemophilus 
ducreyi DNA, which may coexist with yaws as a 
cause of skin ulcers.16
STATISTICAL ANALYSIS
We double-entered data in Access software, ver-
sion 14.0 (Microsoft), with discrepancies checked 
against original forms. Using Stata software, ver-
sion 13.1 (StataCorp), we calculated the prevalence 
of active yaws, assessing everyone in the study 
population at three time points. We estimated 
the prevalence of latent yaws in subgroups of 
children in randomly selected villages. We calcu-
lated that a sample of 875 children would provide 
the study with 80% power to estimate the preva-
lence of high-titer latent yaws with a precision of 
1.5%, at a two-sided significance level of 5%. We 
assumed that the prevalence of high-titer latent 
yaws at 12 months would be 5%.10 We estimated 
that this sample size would provide the study 
with 100% power to detect a prevalence differ-
ence of 11.8 percentage points between baseline 
and the 12-month follow-up.
We estimated the prevalence ratio for the 
comparison of active and latent yaws at three 
time points using a log-binomial regression 
model. We evaluated the decline in the preva-
lence of PCR-detected infection over time using a 
multinomial logistic-regression model. A P value 
of less than 0.05 was considered to indicate sta-
tistical significance. All P values are two-sided.
R ESULT S
STUDY POPULATION
At baseline, we examined 13,490 of the 16,092 
residents (83.8%). Of the 13,490 participants 
examined, 13,302 received azithromycin, 177 re-
ceived penicillin G benzathine, and 11 declined 
treatment. Treatment with oral drugs was ob-
served directly. The overall rate of treatment cov-
erage during the mass treatment program was 
83.8%, and all the study villages had a coverage 
rate of more than 70.0%.
No severe adverse events attributable to the 
study drug were reported by means of passive 
surveillance during the study. Active surveillance 
of 316 participants from 60 households yielded 
54 participants (17.1%) who reported adverse 
events (all mild), including 30 (9.5%) with nausea 
or abdominal pain, 25 (7.9%) with diarrhea, and 
15 (4.7%) with vomiting (Table S1 in the Supple-
mentary Appendix).
Coverage rates of screening for active cases 
during the targeted treatment program in 28 
villages were 81.8% at 6 months and 82.2% at 
12 months. The most common reasons for ab-
sence during treatment and follow-up were travel 
and work.
CHANGES IN THE PREVALENCE OF ACTIVE DISEASE
The prevalence of infectious active yaws fell from 
2.4% at baseline to 0.3% at 6 months and re-
mained at 0.3% at 12 months (difference from 
baseline, 2.1 percentage points; 95% confidence 
interval [CI], 1.9 to 2.4; P<0.001) (Table 1). In all 
the surveys, the community burden of yaws- 
Table 1. Prevalence of Clinically Active Yaws.
Time 
Point
No. of Persons 
Examined
Serologically Confirmed  
Active Yaws
Clinically Suspected Lesions  
with Negative Serologic Findings
No. of Persons 
(%)
Prevalence Ratio  
(95% CI)*
No. of Persons 
(%)
Prevalence Ratio  
(95% CI)*
Baseline 13,490 323 (2.4) 1.00 367 (2.7) 1.00
6 mo 13,166 44 (0.3) 0.14 (0.10–0.19) 77 (0.6) 0.22 (0.17–0.27)
12 mo 13,204 34 (0.3) 0.11 (0.08–0.15) 82 (0.6) 0.23 (0.18–0.29)
* The prevalence ratio was calculated by means of the log-binomial regression model. The baseline prevalence is the ref-
erence value. P<0.001 for the comparison with baseline.
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related ulcers was disproportionately borne by 
children 15 years of age or younger (Fig. 1). Sim-
ilarly, there was a decline in the proportion of 
participants with clinically suspicious lesions and 
negative serologic findings, with significant reduc-
tions from 2.7% at baseline to 0.6% at 12 months 
(difference, 2.1 percentage points; 95% CI, 1.8 to 
2.4; P<0.001). Because H. ducreyi is also a major 
pathogen in skin ulcers on Lihir Island,17 mass 
treatment probably also reduced the burden of 
lesions caused by H. ducreyi.
Most active cases of yaws that were identified 
at resurveys occurred in local residents who had 
been absent from initial treatment surveys: 33 of 
44 cases (75.0%) at 6 months, and 21 of 34 
(61.8%) at 12 months. Some yaws lesions oc-
curred in nontreated visitors or migrants: 2 cases 
(4.5%) at 6 months, and 4 (11.8%) at 12 months. 
A total of 9 cases of ulcers (20.5%) at 6 months 
and 9 (26.5%) at 12 months occurred in previ-
ously treated long-term residents of Lihir Island. 
Of these 18 cases, 11 could be traced directly to 
contact with infectious visitors or untreated lo-
cal residents (i.e., probable reinfection), but no 
source of reinfection was found in 7 cases that 
could have been due to a relapse of an inade-
quately treated latent infection.
CHANGES IN THE PREVALENCE OF LATENT YAWS
Table 2 shows cross-sectional surveys for latent 
yaws in asymptomatic children from randomly 
selected villages. At baseline, we obtained blood 
samples from 991 children; 874 children were test-
ed at 6 months, and 910 were tested at 12 months. 
The mean (±SD) ages of the children were 
10.4±3.6 years, 10.4±3.2 years, and 10.0±3.7 years 
at the baseline, 6-month, and 12-month surveys, 
respectively. No significant differences were seen 
in the ratio of boys to girls at the three time 
points.
The prevalence of high-titer latent yaws de-
creased from 18.3% at baseline to 6.5% at 12 
months (difference, 11.8 percentage points; 95% 
CI, 8.9 to 14.7; P<0.001) (Table 2), with major 
declines in titer from 6 to 12 months. This result 
suggests that decreases in titer require a pro-
longed time after treatment. We also noted a 
significant reduction in the prevalence of all 
seropositive results, from 32.8% at baseline to 
16.4% at 12 months (difference, 16.4 percentage 
points; 95% CI, 12.6 to 20.2; P<0.001).
In subgroup analyses, the prevalence of high-
titer seropositivity in the group of children 1 to 
5 years of age fell significantly, from 13.7% at 
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Figure 1. Prevalence of Active Disease over Time in Various Age Groups.
Table 2. Prevalence of Latent Yaws.
Time 
Point
No. of Children 
Tested All Cases of Latent Yaws* High-Titer Latent Yaws†
No. of  
Children (%)
Prevalence Ratio 
(95% CI)‡
No. of  
Children (%)
Prevalence Ratio
(95% CI)‡
Baseline 991 325 (32.8) 1.00 181 (18.3) 1.00
6 mo 874 261 (29.9) 0.91 (0.80–1.04) 123 (14.1) 0.77 (0.62–0.95)
12 mo 910 149 (16.4) 0.50 (0.42–0.59) 59 (6.5) 0.36 (0.27–0.47)
* The analysis included all seropositive children with a reactive result on the Treponema pallidum hemagglutination assay 
(TPHA) and with a rapid plasma reagin (RPR) titer of at least 1:2.
† The analysis included children with a reactive result on the TPHA and with an RPR titer of at least 1:16.
‡ The prevalence ratio was calculated with the use of a log-binomial regression model. The baseline prevalence is the ref-
erence value. P<0.001 for the comparison with baseline.
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baseline to 0.9% at 12 months (difference, 
12.8 percentage points; 95% CI, 6.3 to 19.3; 
P = 0.02). The change in prevalence in the group 
of children 6 to 15 years of age was also signifi-
cant (difference, 11.6 percentage points; 95% CI, 
8.4 to 14.8; P<0.001) (Table 3).
PROPORTION OF PCR-Confirmed ULCERS DUE  
TO YAWS
PCR analyses of lesion swabs to detect T. pallidum 
subspecies pertenue and H. ducreyi DNA were 
available for 90 participants at baseline, for 84 at 
6 months, and for 114 at 12 months. A bacterial 
cause was identified in 73 participants (81.1%) 
at baseline, in 73 (86.9%) at 6 months, and in 72 
(63.2%) at 12 months. Overall, 70 of 288 people 
(24.3%) who were tested in the three rounds had 
a negative result on all molecular tests.
At baseline, T. pallidum subspecies pertenue alone 
was identified in 19 of 90 participants (21.1%), 
H. ducreyi alone in 42 (46.7%), and co infection 
with both organisms in 12 (13.3%), as reported 
previously.16 Although the prevalence of active 
lesions due to any cause was greatly reduced 
6 months after treatment, the proportion of pa-
tients with lesions due to yaws did not decrease 
significantly, as compared with baseline, and 
the proportion of patients with dual infection 
increased (Table 4). However, at 12 months, 
there was a significant reduction in the propor-
tion of ulcers containing either T. pallidum sub-
species pertenue alone (risk difference, 10.6 per-
centage points; 95% CI, 0.4 to 20.7; P = 0.04) or 
coinfection (risk difference, 7.2 percentage points; 
95% CI, −1.1 to 15.5; P = 0.08), whereas the pro-
portion of ulcers containing H. ducreyi alone 
Table 4. Results of Polymerase-Chain-Reaction Assay of Lesion Swabs.*
Time 
Point
Participants  
Tested
Treponema pallidum 
Subspecies pertenue 
Only Detected
Dual Infection 
Detected
Hae mophilus ducreyi 
Only Detected
Negative  
in All Tests
no. no. of participants (%)
Baseline 90 19 (21.1) 12 (13.3) 42 (46.7) 17 (18.9)
6 mo 84 14 (16.7) 27 (32.1) 32 (38.1) 11 (13.1)
12 mo 114 12 (10.5) 7 (6.1) 53 (46.5) 42 (36.8)
* P<0.001 by the chi-square test for the between-group comparison within each type of infection.
Table 3. Subgroup Analyses of the Prevalence of Latent Yaws.
Time Point Children 1–5 Yr of Age Children 6–15 Yr of Age
No. of 
Children 
Tested
All Cases  
of Latent Yaws*
High-Titer  
Latent Yaws†
No. of 
Children 
Tested
All Cases  
of Latent Yaws*
High-Titer  
Latent Yaws†
no. of  
children (%)
prevalence
ratio
(95% CI)‡§
no. of  
children (%)
prevalence  
ratio
(95% CI)‡¶
no. of  
children (%)
prevalence  
ratio
(95% CI)‡‖
no. of  
children (%)
prevalence  
ratio
(95% CI)‡‖
Baseline 117 26
(22.2)
1.00 16
(13.7)
1.00 874 299 (34.2) 1.00 165
(18.9)
1.00
6 mo 77 10
(13.0)
0.58
(0.30–1.14)
6
(7.8)
0.57
(0.23–1.39)
797 251 (31.5) 0.92
(0.80–1.06)
117
(14.7)
0.78 
(0.63–0.97)
12 mo 114 6
(5.3)
0.24
(0.10–0.55)
1
(0.9)
0.06
(0.01–0.48)
796 143 (18.0) 0.53
(0.44–0.63)
58
(7.3)
0.39
(0.29–0.51)
* The analysis included all seropositive children with a reactive TPHA and RPR titer of at least 1:2.
† The analysis included children with a reactive TPHA and RPR titer of at least 1:16.
‡ The prevalence ratio was calculated with the use of a log-binomial regression model. The baseline prevalence is the reference value.
§ P = 0.003 for the comparison with baseline.
¶ P = 0.02 for the comparison with baseline.
‖ P<0.001 for the comparison with baseline.
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remained at a level similar to the baseline level 
(risk difference, 0.1 percentage points; 95% CI, 
−13.6 to 14.0; P = 0.98). At all the time points, 
clusters of T. pallidum subspecies pertenue were 
identified among family members.
All 91 confirmed specimens for yaws in the 
three surveys were positive for several different 
T. pallidum gene targets and had a tprL molecular 
signature that identified them as subspecies 
pertenue. All T. pallidum samples obtained before 
and after mass treatment had wild-type 23S ribo-
somal DNA findings at positions 2058 and 2059, 
a finding that is consistent with susceptibility to 
azithromycin.
DISCUSSION
Our study showed that one round of mass treat-
ment with azithromycin greatly reduced the 
transmission and endemicity of yaws in Papua 
New Guinean villages that had high baseline 
rates of infection. Implementation of the WHO 
strategy reduced clinical manifestations (ulcers 
and papillomas) by 90%, thus reducing the likeli-
hood of transmission of infection to susceptible 
(uninfected) persons. This hypothesis is support-
ed by the near-absence of high-titer seroreactivity 
among children 1 to 5 years of age (with seroreac-
tivity in these young children indicating relatively 
recent infection) and by reductions in the propor-
tion of skin ulcers attributable to yaws (confirmed 
by means of species-specific PCR assay). The in-
tervention also reduced the proportion of sero-
positive persons, who may be at risk for clinical 
reactivation, and there was no evidence of resis-
tance to azithromycin after mass treatment. These 
results support the use of the Morges strategy for 
the elimination of yaws.
However, our findings suggest that 80% popu-
lation coverage in mass treatment is not suffi-
cient to extinguish local transmission, findings 
that highlight the importance of WHO recom-
mendations of nearly 100% coverage during ini-
tial mass treatment and implementation of sub-
sequent resurveys to detect and treat residual 
cases. The number and frequency of resurveys 
that are necessary to achieve elimination is un-
known. Monitoring will be needed until no more 
cases of active yaws are found and serologic tests 
among children 1 to 5 years of age prove negative.
Our study has several limitations. First, there 
was no untreated control group. Although a 
cluster-randomized trial design would have pro-
vided stronger evidence of effect, we can reason-
ably assume that the decrease in transmission and 
endemicity of yaws is attributable to mass treat-
ment with an antibiotic agent. Second, the effect 
of rainfall on the prevalence of active yaws has 
been well documented, and this effect may have 
biased our results.21 However, both the baseline 
survey and the 12-month survey were conducted 
during the wet season, and there was a decline 
in active yaws cases between these two surveys. 
Finally, elimination of disease is generally easier 
to accomplish on islands than in contiguous com-
munities, which raises questions regarding the 
generalizability of our findings. Records show 
more than 1000 visitors per month between the 
mainland and Lihir Island, but the risk of local 
transmission from imported cases is low be-
cause staff at rural health facilities have been 
carefully trained to recognize yaws lesions. Peri-
odic resurveys must be maintained, however, to 
consolidate the achievements of mass treatment 
and to ensure the elimination of yaws.
In summary, we observed a sustained quanti-
tative reduction in the prevalence of yaws that 
was most likely due to mass treatment with 
azithromycin. In addition, macrolide resistance 
in T. pallidum subspecies pertenue was monitored, 
and no emergence of common resistance muta-
tions was seen; however, close monitoring is 
required both for the emergence of resistance 
mutations in yaws and for the effect of macro-
lide resistance on other colonizing flora. Although 
the reintroduction of infection is a potential 
risk, the magnitude of this risk depends on the 
adequacy of surveillance. Our findings provide 
evidence of the effectiveness of the WHO strategy 
regarding yaws. If this strategy is similarly effec-
tive in other communities, if a high level of aware-
ness among health workers and the populations 
is maintained, and if political and financial 
commitments are forthcoming, the control and 
potential eradication of yaws may be attainable.
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